基因组分类器与局限性前列腺癌的预后:一项系统评价
该系统评价纳入39项研究(37项为回顾性研究),涉及超过10000例局限性前列腺癌患者,评估Decipher、GPS和Prolaris三种基因组分类器对生化复发、转移和前列腺癌特异性死亡的预后能力。基于极低至低确定性证据,三种分类器相比标准临床风险分类方案对上述结局均有小幅但一致的预后改善。
要点
- 39项研究中22项评估Decipher、5项评估GPS、14项评估Prolaris,34项纳入前列腺切除术患者。
- 基于极低至低确定性证据,三种基因组分类器对生化复发、转移和前列腺癌特异性死亡的预后能力均较标准临床风险分类方案有小幅改善。
- 证据确定性降级主要源于回顾性研究偏倚、治疗异质性和患者治疗年代(即2000年代之前)。
核心结论
- 基因组分类器对临床分类方案的预后能力有小幅但一致的改善,在治疗决策不确定时可能有帮助。
- 需要当前管理年代的数据以及这些检测预测能力的证据。
研究设计与样本
- 系统评价,检索MEDLINE、Embase和Web of Science从2010年1月至2022年4月发表的报告。
- 纳入报告局限性前列腺癌患者预后的前瞻性或回顾性研究。
- 共纳入39项研究(37项为回顾性研究),涉及超过10000例患者;22项评估Decipher,5项评估GPS,14项评估Prolaris;34项研究纳入接受前列腺切除术的患者。
- 使用预后研究质量评估工具(QUIPS)评估偏倚风险,采用GRADE并结合预后研究适应性评估证据确定性。
主要发现
- 基于极低至低确定性证据,三种基因组分类器各自对生化复发、转移和前列腺癌特异性死亡的预后能力均较标准临床风险分类方案有小幅改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据信心降级主要源于回顾性研究性质导致的偏倚、接受治疗的异质性以及患者治疗的年代(即2000年代之前)。
- 需要当前管理年代的数据以及这些检测预测能力的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Refinement of the risk classification for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classifiers, Decipher, GPS, and Prolaris, for biochemical recurrence, development of metastases and prostate cancer-specific mortality in patients with localized prostate cancer. METHODS: Data sources: MEDLINE, Embase, and Web of Science were queried for reports published from January 2010 to April 2022. STUDY SELECTION: prospective or retrospective studies reporting prognosis for patients with localized prostate cancer. DATA EXTRACTION: relevant data were extracted into a customized database by one researcher with a second overreading. Risk of bias was assessed using a validated tool for prognostic studies, Quality in Prognosis Studies (QUIPS). Disagreements were resolved by consensus or by input from a third reviewer. We assessed the certainty of evidence by GRADE incorporating adaptation for prognostic studies. RESULTS: Data synthesis: a total of 39 studies (37 retrospective) involving over 10,000 patients were identified. Twenty-two assessed Decipher, 5 GPS, and 14 Prolaris. Thirty-four studies included patients who underwent prostatectomy. Based on very low to low certainty of evidence, each of the three genomic classifiers modestly improved upon the prognostic ability for biochemical recurrence, development of metastases, and prostate cancer-specific mortality compared to standard clinical risk-classification schemes. LIMITATIONS: downgrading of confidence in the evidence stemmed largely from bias due to the retrospective nature of the studies, heterogeneity in treatment received, and era in which patients were treated (i.e., prior to the 2000s). CONCLUSIONS: Genomic classifiers provide a small but consistent improvement upon the prognostic ability of clinical classification schemes, which may be helpful when treatment decisions are uncertain. However, evidence from current management-era data and of the predictive ability of these tests is needed.
引用
- Boyer MJ, Carpenter DJ, Gingrich JR, et al. Genomic classifiers and prognosis of localized prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2024. PMID: 38200096. doi:10.1038/s41391-023-00766-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。